CTRV
If CTRV becomes a $100M mkt cap, pricing hits $130.00 a share!If CTRV becomes a $100M mkt cap, pricing hits $130.00 a share!
CTRV target is at least 340 Day SMA (bought at $8.66 on 6.14.19)CTRV target is at least 340 Day SMA (bought at $8.66 on 6.14.19)
Bought CTRV this morning $8.66 premarket - Qtrly model buy pointBought CTRV for record this morning for $8.66 in premarket
$CTRV 1st Conference Starts Tmrw Continues in the Right DrtnNothing entirely new to report. Closed above last major resistance and still continues to stair step in the right direction. I think it should be noted and I didn't mention it before but the corporations who took a stake in the company in the last two months:
Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Noble Financial reaffirmed a “Buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st.
Teachers Advisors LLC boosted its position by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares worth $1,820,000
Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares worth $3,626,000 after buying an additional 189,634 shares during the last quarter.
Geode Capital Management LLC boosted its position by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares worth $626,000 after buying an additional 7,057 shares during the last quarter.
Morgan Stanley boosted its position in ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares worth $493,000 after buying an additional 1,119 shares during the last quarter.
5.49% of the stock is owned by institutional investors.
Very nice averages stakes taken by numerous groups and this is a month or two before the conferences. Shows some agencies might have gotten a sneak peak at the upcoming info. $CTRV
$CTRV Continues to trend upwards Amid Bio Conferences$CTRV announced today in addition to the 2017 Marcum MicroCap Conference 15-16 in New York, they will also be presenting at the San Diego Bio conference on June 19-22.
Let's think about this hypothetically. If there was no news to present or bad news they wouldn't have more than one conference, I mean one conference would be more than enough to tell everything in either of those two cases also who wants to put themselves through the embarrassment of a second conference if there wasn't something good down the line. Only time will tell but it is looking good in the right direction.
Also the techs are beyond bullish EMA / SMA crossover, PARSAR flip, resistance breaks support rebounds higher highs higher lows. All around very good.
pbs.twimg.com
$CTRV Runway Is Cleared for Take-Off$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to move a stock and takes care of his shareholders while at the same time taking care of the company and business. Not to mention 3 drug candidates in clinical trials. Liking what I'm seeing here.
